Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Discontinued
Reference number: GID-TA11018
As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108].
For information, the company have advised that they are no longer pursuing an extension to the existing Conditional Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.